NCT03791138 (TANGO) is a NA clinical trial of online patient decision aid in Breast Cancer, sponsored by The Netherlands Cancer Institute.

Who is sponsoring NCT03791138?

NCT03791138 is sponsored by The Netherlands Cancer Institute.

What drugs are being tested in NCT03791138?

Interventions in NCT03791138: online patient decision aid.

What condition does NCT03791138 study?

NCT03791138 studies Breast Cancer.

Is NCT03791138 still recruiting?

NCT03791138 is currently completed. Last updated 6 June 2022.

Last reviewed 2022-06-06 · How we verify

NCT03791138: TANGO

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Impact of a Web-based Patient Decision Aid for Women Considering Breast Reconstruction

Completed NA Last updated 6 June 2022

What this trial tests

NA trial testing online patient decision aid in Breast Cancer in 250 participants. Completed in 8 October 2020.

Timeline

16 August 2017

Primary endpoint
28 May 2019

8 October 2020

Quick facts

Lead sponsor	The Netherlands Cancer Institute
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	250
Start date	16 August 2017
Primary completion	28 May 2019
Estimated completion	8 October 2020
Sites	8 locations across Netherlands

Drugs / interventions tested

online patient decision aid

Conditions studied

Breast Cancer — all drugs for Breast Cancer →

Sponsor

The Netherlands Cancer Institute

Who can join

18 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study evaluates the impact of an online patient decision aid on the process of decision making regarding breast reconstruction and the decision quality in women with breast cancer undergoing mastectomy and considering immediate breast reconstruction. Half of participants will receive care as usual and access to the online decision aid, while the other half will receive care as usual including a standard information leaflet.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Decision aids for people facing health treatment or screening decisions.
Stacey D, Lewis KB, Smith M, Carley M, et al · · 2024 · cited 203× · PMID 38284415 · DOI 10.1002/14651858.cd001431.pub6
The impact of an online patient decision aid for women with breast cancer considering immediate breast reconstruction: study protocol of a multicenter randomized controlled trial.
Ter Stege JA, Woerdeman LAE, Hahn DEE, van Huizum MA, et al · · 2019 · cited 20× · PMID 31426772 · DOI 10.1186/s12911-019-0873-1
Efficacy of a Decision Aid in Breast Cancer Patients Considering Immediate Reconstruction: Results of a Randomized Controlled Trial.
Ter Stege JA, Woerdeman LAE, Kieffer JM, Sherman KA, et al · · 2024 · cited 5× · PMID 37815283 · DOI 10.1097/prs.0000000000011100

Verify or expand the search:

Other recruiting trials for Breast Cancer

Currently open trials in the same condition.

NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting

Other The Netherlands Cancer Institute trials

Trials by the same sponsor.

NCT07436858 — Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER · Phase 1 · not yet recruiting
NCT07071727 — Short Course of Radiotherapy Prior to Surgery of Soft Tissue Sarcomas · NA · recruiting
NCT06931769 — TAO-Towards Optimal (Neo)Adjuvant Systemic Therapy of Stage III Triple-negative Breast Cancer · recruiting
NCT06273800 — Chemosensitivity During Phases of the Menstrual Cycle in Breast Cancer Patients · NA · recruiting
NCT07310758 — Contrast-enhanced Ultrasound for Sentinel Node Detection · Phase 2, PHASE3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03791138 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The Netherlands Cancer Institute
Last refreshed: 6 June 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03791138.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing